United States· US:11994-011_8b5860ab-6714-4cf0-8679-f7c439fe5131
Definity
A perflutren product containing perflutren, registered in United States by Lantheus Medical Imaging, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PERFLUTREN
- Manufacturer
- Lantheus Medical Imaging, Inc.
- Country
- United States (US)
- ATC code
- Perflutren
- ATC class
- Perflutren
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 6
- ndc1111994011011 VIAL, GLASS in 1 CARTON (11994-011-01) / 1.5 mL in 1 VIAL, GLASS
- ndc1111994011044 VIAL, GLASS in 1 CARTON (11994-011-04) / 1.5 mL in 1 VIAL, GLASS
- ndc11119940111616 VIAL, GLASS in 1 CARTON (11994-011-16) / 1.5 mL in 1 VIAL, GLASS
- ndc1111994-011-01
- ndc1111994-011-04
- ndc1111994-011-16
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Perflutren in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLUMINITYLantheus EU Limited, Shannon
- SpainLUMINITY 150 MICROLITROS/ML GAS Y DISOLVENTE PARA SOLUCIÓN PARA DISPERSIÓN INYECTABLE Y PARA PERFUSIÓNLantheus Eu Limited
- SwedenLuminity 150 mikroliter/ml Injektions-/infusionsvätska, dispersionLantheus EU Limited
- BelgiumLuminity 150 µl/mlLantheus EU
- FinlandLuminityLantheus EU Limited
- United KingdomLuminity 225microlitres/1.5ml gas and solvent for dispersion for injection vialsPharmanovia Benelux B.V.
- IcelandLuminityLantheus EU Limited
- NetherlandsLuminity 150 microliter/ml oplossing voor dispersie voor injectie of infusieLantheus EU Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Optison
- Iceland · Optison
- Liechtenstein · Optison
- Norway · Optison
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/65c223dc-a556-4c9c-9abc-b63b65c13b00 GET /v1/drugs/65c223dc-a556-4c9c-9abc-b63b65c13b00?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "6.52",
"substance": "PERFLUTREN",
"productndc": "11994-011",
"dosage_form": "INJECTION, SUSPENSION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "NDA021064",
"marketing_category": "NDA"
}See everything about perflutren.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.